Verrica Pharmaceuticals Inc.

VRCA Nasdaq SEC CIK 1660334
Follow Verrica Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $6.9M −51.8% vs same quarter last year
Net income −$12.4M −4428.1% vs same quarter last year
EPS, diluted −$0.58 −1833.3% vs same quarter last year
Operating cash flow −$9M −193.3% vs same quarter last year
Revenue by quarter
$344K
$3.4M
$12.7M
$14.3M
$5.1M
$5M
$5.9M
$6.9M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
  • Revenue
  • Net income
−$100M−$50M$0$50MFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$35.6M−$17.9M
FY24$7.6M−$76.6M
FY23$5.1M−$67M
FY22$9M−$24.5M
FY21$12M−$35.1M
FY20-−$42.7M
FY19-−$28.2M
FY18-−$20.6M
FY17-−$4.5M
FY16--
MarginsShare of revenue
  • Operating margin
  • Net margin
−1500%−1000%−500%0%FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−34.2%−50.3%
FY24−871.3%−1012.4%
FY23−1283.4%−1307.6%
FY22−235.8%−271.1%
FY21−257.6%−292.3%
FY20--
FY19--
FY18--
FY17--
FY16--
Free cash flowOperating cash flow minus capital expenditure
−$80M−$60M−$40M−$20M$0FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$17.6M
FY24−$61M
FY23−$38.9M
FY22−$19M
FY21−$28.5M
FY20−$31.7M
FY19−$28.1M
FY18−$18.6M
FY17-
FY16-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Verrica Pharmaceuticals
  • Healthcare median
−1500%−1000%−500%0%FY17FY19FY21FY23FY25
Show the numbers
YearVerrica PharmaceuticalsHealthcare median
FY25−50.3%−30.6%
FY24−1012.4%−47%
FY23−1307.6%−58%
FY22−271.1%−80.4%
FY21−292.3%−71.8%
FY20-−62.2%
FY19-−46.2%
FY18-−49.6%
FY17-−45.9%
FY16-−36%